+

WO2013167995A3 - Compositions and methods for the treatment of hyperglycemia - Google Patents

Compositions and methods for the treatment of hyperglycemia Download PDF

Info

Publication number
WO2013167995A3
WO2013167995A3 PCT/IB2013/050903 IB2013050903W WO2013167995A3 WO 2013167995 A3 WO2013167995 A3 WO 2013167995A3 IB 2013050903 W IB2013050903 W IB 2013050903W WO 2013167995 A3 WO2013167995 A3 WO 2013167995A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
complications
treatment
hyperglycemia
compositions
Prior art date
Application number
PCT/IB2013/050903
Other languages
French (fr)
Other versions
WO2013167995A2 (en
Inventor
Mahesh Kandula
Original Assignee
Cellixbio Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellixbio Private Limited filed Critical Cellixbio Private Limited
Priority to AU2013257716A priority Critical patent/AU2013257716A1/en
Priority to CA2873087A priority patent/CA2873087A1/en
Priority to JP2015510897A priority patent/JP2016510306A/en
Priority to SG11201407316QA priority patent/SG11201407316QA/en
Priority to CN201380030654.2A priority patent/CN104812737A/en
Publication of WO2013167995A2 publication Critical patent/WO2013167995A2/en
Publication of WO2013167995A3 publication Critical patent/WO2013167995A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of hyperglycemia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, and post prandial hyperglycemia.
PCT/IB2013/050903 2012-05-08 2013-02-03 Compositions and methods for the treatment of hyperglycemia WO2013167995A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2013257716A AU2013257716A1 (en) 2012-05-08 2013-02-03 Compositions and methods for the treatment of hyperglycemia
CA2873087A CA2873087A1 (en) 2012-05-08 2013-02-03 Compositions and methods for the treatment of hyperglycemia
JP2015510897A JP2016510306A (en) 2012-05-08 2013-02-03 Compositions and methods for the treatment of hyperglycemia
SG11201407316QA SG11201407316QA (en) 2012-05-08 2013-02-03 Compositions and methods for the treatment of hyperglycemia
CN201380030654.2A CN104812737A (en) 2012-05-08 2013-02-03 Compositions and methods for treatment of hyperglycemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1811/CHE/2012 2012-05-08
IN1811CH2012 2012-05-08

Publications (2)

Publication Number Publication Date
WO2013167995A2 WO2013167995A2 (en) 2013-11-14
WO2013167995A3 true WO2013167995A3 (en) 2016-09-01

Family

ID=54193690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/050903 WO2013167995A2 (en) 2012-05-08 2013-02-03 Compositions and methods for the treatment of hyperglycemia

Country Status (6)

Country Link
JP (1) JP2016510306A (en)
CN (1) CN104812737A (en)
AU (1) AU2013257716A1 (en)
CA (1) CA2873087A1 (en)
SG (1) SG11201407316QA (en)
WO (1) WO2013167995A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016198971A1 (en) * 2015-06-08 2016-12-15 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643874A (en) * 1993-08-05 1997-07-01 Hoffmann-La Roche Inc. Pharmaceutical composition comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
WO2004007524A2 (en) * 2002-07-17 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic oligopeptides
EP1903034A1 (en) * 2006-09-19 2008-03-26 Technische Universität Graz Iminosugar glycoconjugates

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
JPS5283951A (en) * 1976-01-01 1977-07-13 Nippon Shinyaku Co Ltd Remedy for hyperglycemia and depressant for lipid-biosythesis
JPS5943946B2 (en) * 1978-04-28 1984-10-25 日本新薬株式会社 N-alkenylmoranoline derivative
DE3737523A1 (en) * 1987-11-05 1989-05-18 Bayer Ag USE OF SUBSTITUTED HYDROXYPIPERIDINES AS ANTIVIRAL AGENTS
EP0330468A3 (en) * 1988-02-23 1991-04-03 Glaxo Group Limited Use of heterocyclic derivatives as kappa-opioid receptor agonists in the treatment of cerebral ischaemia
JPH06329671A (en) * 1993-05-21 1994-11-29 Tsumura & Co New alkaloid and its use
CA2646729A1 (en) * 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence
CN101129476B (en) * 2006-08-21 2013-07-24 中国医学科学院药物研究所 Application of mulberry twigs alkaloid valid target in preparing antidiabetics medicament
EP2152276A4 (en) * 2007-05-09 2011-09-14 Traffick Therapeutics Inc Screening assay to identify correctors of protein trafficking defects
GB0809360D0 (en) * 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
EP2323652A2 (en) * 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
KR101828616B1 (en) * 2010-01-08 2018-02-12 카타베이시스 파마슈티칼즈, 인코포레이티드 Fatty acid fumarate derivatives and their uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643874A (en) * 1993-08-05 1997-07-01 Hoffmann-La Roche Inc. Pharmaceutical composition comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
WO2004007524A2 (en) * 2002-07-17 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic oligopeptides
EP1903034A1 (en) * 2006-09-19 2008-03-26 Technische Universität Graz Iminosugar glycoconjugates

Also Published As

Publication number Publication date
WO2013167995A2 (en) 2013-11-14
JP2016510306A (en) 2016-04-07
CN104812737A (en) 2015-07-29
SG11201407316QA (en) 2014-12-30
AU2013257716A1 (en) 2014-11-27
CA2873087A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
EA201070477A1 (en) TRANS-CLOMIFEN FOR THE TREATMENT OF METABOLIC SYNDROME
WO2010018549A3 (en) Therapeutic compositions containing macitentan
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
MX365108B (en) Piperidine derivatives for gpr119 agonist.
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2008098978A3 (en) Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
WO2014174425A3 (en) Compositions and methods for the treatment of orthostasis and neurological diseases
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014080307A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2013167995A3 (en) Compositions and methods for the treatment of hyperglycemia
WO2012011707A3 (en) Substituted pyridinone derivatives and methods for manufacturing the same
WO2014195810A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2013167998A3 (en) Compositions and methods for the treatment of autonomic and other neurological disorders
WO2013167997A3 (en) Compositions and methods for the treatment of metabolic syndrome
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2014083476A3 (en) Compositions and methods for the treatment of metabolic and lipid disorders
WO2014068461A3 (en) Compositions and methods for the treatment of acute inflammation
WO2015015403A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2873087

Country of ref document: CA

Ref document number: 2015510897

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013787060

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013257716

Country of ref document: AU

Date of ref document: 20130203

Kind code of ref document: A

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载